论文部分内容阅读
目的:探讨替米沙坦对高血压大鼠肾组织podocalyxin(PCX)表达的影响及作用。方法:30只雄性SD大鼠随机分为高血压组(A组)、替米沙坦组(B组)、对照组(C组)。以改进的“两肾一夹”方法建立高血压大鼠模型。B组从造模后5周始给予替米沙坦5mg·kg~(-1)·d~(-1)混悬液灌胃,共用药6周。观察收缩压(SBP),分别于实验前、用药前、用药后6周检测3组大鼠的尿β_2-微球蛋白(β_2-MG)、血尿素氮(BUN)及血肌酐(Scr)水平;免疫组化方法观察PCX在肾组织的表达,并分析PCX的积分吸光度(IA)值;观察肾脏病理及足细胞超微结构改变。结果:用药前A组及B组SBP较C组显著升高(P<0.01);用药后B组SBP较A组显著降低(P<0.01)。A组β_2-MG显著高于C组(P<0.01);用药后B组尿β_2-MG显著低于A组(P<0.01),3组BUN、Scr在整个实验过程中无显著差异。A组、B组肾脏发生病理及足细胞超微结构改变。经替米沙坦治疗后,B组肾脏病理变化及足细胞超微结构改变均有缓解。并可上调PCX蛋白的表达。结论:替米沙坦可减少蛋白尿,缓解高血压肾损害和足细胞损伤。并可上调PCX蛋白的表达从而发挥保护足细胞的功能。
Objective: To investigate the effect of telmisartan on the expression of podocalyxin (PCX) in renal tissue of hypertensive rats. Methods: Thirty male Sprague-Dawley rats were randomly divided into hypertension group (group A), telmisartan group (group B) and control group (group C). Hypertensive rat model was established by improved “two kidneys and one clip” method. The rats in group B were treated with Telmisartan 5 mg · kg -1 d -1 for 6 weeks. The systolic blood pressure (SBP) was observed and the urinary β_2-microglobulin (β_2-MG), blood urea nitrogen (BUN) and serum creatinine (Scr) levels of the three groups were measured before treatment, The immunohistochemical method was used to observe the expression of PCX in renal tissue. The integral absorbance (IA) value of PCX was analyzed. The pathological changes of kidney and ultrastructure of podocyte were observed. Results: The SBP in group A and group B before treatment were significantly higher than those in group C (P <0.01). After treatment, the SBP in group B was significantly lower than that in group A (P <0.01). The β_2-MG in group A was significantly higher than that in group C (P <0.01). The urinary β_2-MG in group B after treatment was significantly lower than that in group A (P <0.01). There was no significant difference in BUN and Scr among the three groups. Pathological changes of renal tissue and changes of podocyte ultrastructure were observed in group A and group B. After treatment with telmisartan, the renal pathological changes and ultrastructural changes of podocytes in group B were relieved. And can up-regulate the expression of PCX protein. Conclusion: Telmisartan can reduce proteinuria, relieve hypertensive renal damage and podocyte injury. And can up-regulate the expression of PCX protein to play a role in protecting podocytes.